Journal
PLOS PATHOGENS
Volume 2, Issue 6, Pages 591-602Publisher
PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.ppat.0020059
Keywords
-
Categories
Funding
- NCI NIH HHS [R01 CA074131, 5R01CA074131] Funding Source: Medline
- NIAID NIH HHS [U19 AI048214, 5U19AI48214] Funding Source: Medline
- NIDA NIH HHS [R01DA16078, R37 DA004334, R01DA12568, 1R37DA004334, R01 DA016078, R01 DA012568, 1P30DA01562501] Funding Source: Medline
- PHS HHS [5R01A1049168] Funding Source: Medline
Ask authors/readers for more resources
The severe combined immunodeficiency disorder (SCID)-beige/albumin (Alb)-urokinase plasminogen activator (uPA) mouse containing a human-mouse chimeric liver is currently the only small animal model capable of supporting hepatitis C virus (HCV) infection. This model was utilized to characterize the host transcriptional response to HCV infection. The purpose of these studies was to investigate the genetic component of the host response to HCV infection and also to distinguish virus-induced gene expression changes from adaptive HCV-specific immune-mediated effects. Gene expression profiles from HCV-infected mice were also compared to those from HCV-infected patients. Analyses of the gene expression data demonstrate that host factors regulate the response to HCV infection, including the nature of the innate antiviral immune response. They also indicate that HCV mediates gene expression changes, including regulation of lipid metabolism genes, which have the potential to be directly cytopathic, indicating that liver pathology may not be exclusively mediated by HCV-specific adaptive immune responses. This effect appears to be inversely related to the activation of the innate antiviral immune response. In summary, the nature of the initial interferon response to HCV infection may determine the extent of viral-mediated effects on host gene expression.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available